Answers are grounded in this paper and cite their sources.
Introduction We aimed to disentangle whether elevated body mass index (BMI) is directly associated with adverse survival in primary colorectal cancer (CRC), or indirectly through treatment-related mechanisms, e.g., dose-capping adjuvant chemotherapy (ACT) and toxicity, using individual participant data meta-analysis (IPD-MA) and causal inference approaches. Methods Using BMI from four CRC-ACT randomised trials [OCTOPUS], and two ACT adherence measures (average cumulative relative dose [ACRD]; average relative dose intensity [ARDI]), we performed two-stage random effects IPD-MA, assessing total (TE) and direct effects (DE) (excluding and including mediators, respectively) of pre-defined causal paths, with overall survival (OS) as primary outcome. Findings In 7264 patients, the TE of 5 kg/m 2 BMI increments was a significant ACRD reduction (−1.15% [95% CI −1.92, −0.38]), and ACRD 5% increments were associated with improved OS (HR 0.94 [0.91, 0.96]), implying possible adverse indirect effects; though not large enough to induce an adverse TE of BMI on OS (HR 0.98 [0.90, 1.07]). BMI-ARDI relationships were similar (TE −1.08% [−1.44, −0.72]), but ARDI-OS relationships were inverted (HR 1.05 [1.01, 1.09]). BMI showed no association with grade 3+ toxicity (OR 1.01 (0.91, 1.14)). However, toxicity was associated with worse OS (TE HR 1.37 [1.17, 1.61]), which attenuated on adjusting for ACRD (DE HR 1.20 [1.02, 1.41]), suggesting partial mediation via a significant toxicity-ACRD relationship (−10.37% [−11.77, −8.97]). Conclusion Our study establishes possible adverse indirect effects of obesity on CRC survival, through treatment-selection, supporting full BSA-based ACT dosing.
No takes yet. Share an insight, caveat, or question.
Slawinski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: